Kaminie Moodley1, Pierre L A Bill2, Ahmed I Bhigjee2, Vinod Bhagu Patel3. 1. Department of Neurology, University of KwaZulu-Natal, Durban, South Africa. Electronic address: Kaminie@live.co.za. 2. Department of Neurology, University of KwaZulu-Natal, Durban, South Africa. 3. Department of Neurology, University of KwaZulu-Natal, Durban, South Africa. Electronic address: patelv@ukzn.ac.za.
Abstract
BACKGROUND: This study is a descriptive review of the clinical and treatment outcome differences in HIV-infected patients with motor neuron syndrome (MNS) and HIV-uninfected patients with motor neuron disease (MND). METHODS: A retrospective analysis of patients with MND/S was performed at Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa between 2003 and 2017. RESULTS: One hundred and thirty six patients were included in the study, 101 (76%) were HIV-uninfected and 35 (26%) were HIV-infected. Ninety four percent of the HIV-infected cohort were <50 years, median 41, IQR (33-45), p < 0.001, had median ALS functional rating scale revised (ALSFRS-R) score of 28, IQR [24-30] and 40% of these patients on anti-retroviral therapy (ART) survived longer than 10 years. Ninety one percent of the HIV-uninfected cohort were >50 years, median 66, IQR(57-74), P < 0.001, had median ALSFRS-R score of 44 (IQR 42-45) and 93% died within 5 years of their illness. CONCLUSION: HIV-infected MNS patients were younger, had more severe disease at presentation and survived longer if treated with ART with possible reversal of the disease process, compared to patients with MND.
BACKGROUND: This study is a descriptive review of the clinical and treatment outcome differences in HIV-infectedpatients with motor neuron syndrome (MNS) and HIV-uninfectedpatients with motor neuron disease (MND). METHODS: A retrospective analysis of patients with MND/S was performed at Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa between 2003 and 2017. RESULTS: One hundred and thirty six patients were included in the study, 101 (76%) were HIV-uninfected and 35 (26%) were HIV-infected. Ninety four percent of the HIV-infected cohort were <50 years, median 41, IQR (33-45), p < 0.001, had median ALS functional rating scale revised (ALSFRS-R) score of 28, IQR [24-30] and 40% of these patients on anti-retroviral therapy (ART) survived longer than 10 years. Ninety one percent of the HIV-uninfected cohort were >50 years, median 66, IQR(57-74), P < 0.001, had median ALSFRS-R score of 44 (IQR 42-45) and 93% died within 5 years of their illness. CONCLUSION:HIV-infected MNSpatients were younger, had more severe disease at presentation and survived longer if treated with ART with possible reversal of the disease process, compared to patients with MND.
Authors: William P Howlett; Sarah J Urasa; Venance P Maro; Richard W Walker; Kajiru G Kilonzo; Patrick J Howlett; Marieke Cj Dekker Journal: Afr Health Sci Date: 2022-03 Impact factor: 1.108
Authors: Marko Melnick; Patrick Gonzales; Thomas J LaRocca; Yuping Song; Joanne Wuu; Michael Benatar; Björn Oskarsson; Leonard Petrucelli; Robin D Dowell; Christopher D Link; Mercedes Prudencio Journal: G3 (Bethesda) Date: 2021-09-06 Impact factor: 3.154